Faster, More Accurate Diagnoses
Reduced pathologist workload by 40% via AI triage of low-risk cases.

The client is an innovative digital pathology startup focused on AI-powered cancer risk assessment with two commercialized products already transforming patient care. Their goal is to transform breast cancer diagnostics by developing a morphology-driven AI platform that predicts recurrence risk from standard H&E slides, enabling personalized treatment plans. With a team of oncologists and data scientists, they seek a technical partner to build a scalable, FDA-cleared diagnostic tool.
The company had groundbreaking research but lacked the technical infrastructure to deploy their AI at scale. The prototype struggled with variability in slide quality, low interoperability with hospital systems, and black-box AI that clinicians distrusted. They needed a secure, production-ready platform that could:
The software is now deployed across 20+ labs, with ongoing trials for prostate cancer adaptation. Highlights include:
Reduced pathologist workload by 40% via AI triage of low-risk cases.
Achieved FDA De Novo clearance in 18 months, with modular design for new cancer types.
30% increase in early-stage recurrence detection in validation studies.
Project summary:
Glorium Technologies provided mobile app development services for a healthcare education organization. Their team helped build an application for COVID-19 relief. The solution features simulation training.
Feedback summary:
The app is being handed off and will soon go live. Glorium Technologies implemented an effective project management style. The engagement had its challenges but their team took the time to resolve issues and deliver on expectations. They follow through on commitments and work in a quick turnaround.